- The Financial Times reports that AstraZeneca's (AZN -0.1%) COVID-19 vaccine agreement with the University of Oxford allows it to make up to 20% over material costs.
- The company previously stated that it intends to sell the vaccine at no profit during the pandemic. The 20% gross margin is not inconsistent with this since other costs have to be accounted for.
- https://seekingalpha.com/news/3625444-astrazeneca-covidminus-19-deal-allows-20-gross-profit
Friday, October 23, 2020
AstraZeneca COVID-19 deal allows 20% gross profit
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.